Low-level laser for Lymphedema

N/A

Waitlist Available

Research Sponsored by Abramson Cancer Center at Penn Medicine

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Be older than 18 years old

Timeline

Screening 3 weeks

Treatment Varies

Follow Up up to 8-week post-lllt

Awards & highlights

No Placebo-Only Group

Summary

This trial is testing low-level laser treatment (LLLT) on head and neck cancer survivors who have lymphedema. LLLT uses light to reduce swelling and improve blood flow, which may help with symptoms like tightness and limited movement. The study aims to see if LLLT can improve their quality of life. Low-level laser therapy (LLLT) has been studied for its effects on reducing inflammation, promoting tissue repair, and relieving pain in various conditions, including breast cancer-related lymphedema.

Eligible Conditions

Lymphedema
Truncal Lymphedema
Head and Neck Cancers
Fibrosis

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ up to 8-week post-lllt

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~up to 8-week post-lllt

This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 8-week post-lllt for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

% of patients with reduced severity of lymphedema and fibrosis

Secondary study objectives

Neck

Quality of life score

Symptom burden score

Awards & Highlights

No Placebo-Only Group

All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups

Experimental Treatment

Active Control

Group I: Group 1 (laser group)Experimental Treatment1 Intervention

Group 1 (laser group): After completion of the baseline measurements, Group 1 participants will be scheduled for LLLT. After completion of LLLT, participants will be scheduled for the 4-week and 8-week follow up data collection.

Group II: Group 2 (wait-list control group)Active Control1 Intervention

Group 2 (wait-list control group): Group 2 participants will not undergo LLLT therapy but will complete all the same study assessments as the laser therapy group, including the baseline, and follow-up assessments. After the 8-week follow-up assessment, participants will be offered the same LLLT as the laser group.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Low-level laser

2020

N/A

~230

Do I qualify?Apply below to find out